ACTR1A

Across TCGA pan-cancer cohorts, ACTR1A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACTR1A data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ACTR1A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACTR1A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and COAD are the cancer types where ACTR1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.835	0.426	.005	30	view →
LUAD	OS	Quartile	II,III,IV	0.671	1.000	.009	12	view →
COAD	DFS	Median	All	0.887	1.000	.020	6	view →
LSCC	DFS	Quartile	II,III,IV	0.423	0.829	.016	5	view →
PDAC	DFS	Quartile	All	0.884	0.765	.023	4	view →
HNSC	DFS	Tertile	III,IV	0.878	0.686	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACTR1A–CCRCC (DFS)

Open the CCRCC breakdown →